Ascletis Initiates Global Phase III Program for Weight Management Drug

Ascletis has dosed the first participant in a global Phase III clinical program for ASC30, a once-daily oral small molecule GLP-1 receptor agonist intended for chronic weight management. The program aims to evaluate the drug's efficacy and safety.

The program is expected to enroll approximately 4,600 participants with obesity or overweight across the U.S., Europe, and Canada. Two pivotal trials, AURORA-1 and AURORA-2, will investigate the effects of three maintenance doses: 20 mg, 40 mg, and 60 mg.

This marks a significant step in the company's drug development pipeline, as it seeks to address the growing need for effective weight management solutions. The global scope of the trials is designed to gather comprehensive data from a diverse patient population.